Erythropoiesis stimulating agents and techniques: A challenge for doping Analysts

Current Medicinal Chemistry

Volumn 16, Issue 10, 2009, Pages 1236-1247

  Jelkmann, W ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Doping; Erythropoietin; Glycosylation; Immunoblotting; Recombinant DNA technology

Indexed keywords

2 OXOGLUTARIC ACID; AMINO ACID; ANTIANEMIC AGENT; CNTO 528; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DIAZEPANE DERIVATIVE; EPOIETIN DELTA; EPOIETIN OMEGA; EPOIETIN ZETA; ERYTHROPOIETIN; FG 2216; GATA INHIBITOR; GLYCAN; HX 575; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR STABILIZER; N GLYCOLOYLNEURAMINIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PARVOVIRUS VECTOR; PROTEIN INHIBITOR; RECOMBINANT ERYTHROPOIETIN; REPOTIN; SB 309; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ATHLETE; CELL LINE; CHO CELL; CLINICAL TRIAL; DOPING; DRUG ACTIVITY; DRUG FORMULATION; DRUG MIXTURE; DRUG STRUCTURE; ERYTHROPOIESIS; EUROPEAN UNION; FIBROSARCOMA; HOMOLOGOUS RECOMBINATION; HUMAN; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; NONHUMAN; PATENT; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; REVIEW; SPORT; URINALYSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CRICETINAE; DOPING IN SPORTS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; IMMUNOBLOTTING; PROTEIN ENGINEERING;

EID: 65649123829     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787846668     Document Type: Review

References (160)

1. World Anti-Doping Agency List. http://www.wada-ama. org/en/ prohibitedlist.ch2.
2. Jelkmann, W. Erythropoietin after a century of research: Younger than ever. Eur. J. Haematol., 2007, 78, 183-205.
3. Debeljak, N.; Sytkowski, A. J. Erythropoietin: New approaches to improved molecular designs and therapeutic alternatives. Curr. Pharm. Des., 2008, 14, 1302-10.
4. Jelkmann, W. Developments in the therapeutic use of erythropoiesis stimulating agents. Br. J. Haematol., 2008, 141, 287-97.
5. Mikhail, A.; Covic, A.; Goldsmith, D. Stimulating erythropoiesis: Future perspectives. Kidney Blood Press Res., 2008, 31, 234-46.
6. Eichner, E. Better dead than second. J. Lab. Clin. Med., 1992, 120, 359-60.
7. Jelkmann, W. Novel erythropoietic agents: A threat to sportsmanship. Med. Sportiva, 2007, 11, 32-42.
8. Delanghe, J.R.; Bollen, M.; Beullens, M. Testing for recombinant erythropoietin. Am. J. Hematol., 2008, 83, 237-41.
9. Elliott, S. Erythropoiesis-stimulating agents and other methods to enhance oxygen transport. Br. J. Pharmacol., 2008, 154, 529-41.
10. Imagawa, S.; Izumi, T.; Miura, Y. Positive and negative regulation of the erythropoietin gene. J. Biol. Chem., 1994, 269, 9038-44.
11. Imagawa, S.; Nakano, Y.; Obara, N.; Suzuki, N.; Doi, T.; Kodama, T.; Nagasawa, T.; Yamamoto, M. A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1beta, TNF-alpha, or L-NMMA. FASEB J., 2003, 17, 1742-4.
12. Galson, D.L.; Tsuchiya, T.; Tendler, D.S.; Huang, L.E.; Ren, Y.; Ogura, T.; Bunn, H.F. The orphan receptor hepatic nuclear factor 4 functions as a transcriptional activator for tissue-specific and hypoxia-specific erythropoietin gene expression and is antagonized by EAR3/COUP-TF1. Mol. Cell Biol., 1995, 15, 2135-44.
13. Semenza, G.L.; Nejfelt, M.K.; Chi, S.M.; Antonarakis, S.E. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1991, 88, 5680-4.
14. Pugh, C.W.; Tan, C.C.; Jones, R.W.; Ratcliffe, P.J. Functional analysis of an oxygen-regulated transcriptional enhancer lying 3′ to the mouse erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1991, 88, 10553-7.
15. Semenza, G.L.; Wang, G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol., 1992, 12, 5447-54.
16. 2-regulated prolyl hydroxylation. Science, 2001, 292, 468-72.
17. 2 sensing. Science, 2001, 292, 464-8.
18. Lando, D.; Peet, D.J.; Whelan, D.A.; Gorman, J.J.; Whitelaw, M.L. Asparagine hydroxylation of the HIF transactivation domain: A hypoxic switch. Science, 2002, 295, 858-61.
19. Rosenberger, C.; Mandriota, S.; Jurgensen, J.S.; Wiesener, M.S.; Horstrup, J.H.; Frei, U.; Ratcliffe, P.J.; Maxwell, P.H.; Bachmann, S.; Eckardt, K.U. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol., 2002, 13, 1721-32.
20. Warnecke, C.; Zaborowska, Z.; Kurreck, J.; Erdmann, V.A.; Frei, U.; Wiesener, M.; Eckardt, K.U. Differentiating the functional role of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha (EPAS-1) by the use of RNA interference: Erythropoietin is a HIF-2alpha target gene in Hep3B and Kelly cells. FASEB J., 2004, 18, 1462-4.
21. Rankin, E.B.; Biju, M.P.; Liu, Q.; Unger, T.L.; Rha, J.; Johnson, R.S.; Simon, M.C.; Keith, B.; Haase, V.H. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J. Clin. Invest., 2007, 117, 1068-77.
22. Recny, M.A.; Scoble, H.A.; Kim, Y. Structural characterization of natural human urinary and recombinant DNA-derived erythropoietin. Identification of des-arginine 166 erythropoietin. J. Biol. Chem., 1987, 262, 17156-63.
23. Rahbek-Nielsen H.; Roepstorff, P.; Reischl, H.; Wozny, M.; Koll, H.; Haselbeck, A. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J. Mass Spectrom., 1997, 32, 948-58.
24. Lai, P.H.; Everett, R.; Wang, F.F.; Arakawa, T.; Goldwasser, E. Structural characterization of human erythropoietin. J. Biol. Chem., 1986, 261, 3116-21.
25. Boissel, J.P.; Lee, W.R.; Presnell, S.R.; Cohen, F.E.; Bunn, H.F. Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J. Biol. Chem., 1993, 268, 15983-93.
26. Sasaki, H.; Bothner, B.; Dell, A.; Fukuda, M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J. Biol. Chem., 1987, 262, 12059-76.
27. Sasaki, H.; Ochi, N.; Dell, A.; Fukuda, M. Site-specific glycosylation of human recombinant erythropoietin: Analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry, 1988, 27, 8618-26.
28. Delorme, E.; Lorenzini, T.; Giffin, J.; Martin, F.; Jacobsen, F.; Boone, T.; Elliott, S. Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry, 1992, 31, 9871-6.
29. Takeuchi, M.; Kobata, A. Structures and functional roles of the sugar chains of human erythropoietins. Glycobiology, 1991, 1, 337-46.
30. Weikert, S.; Papac, D.; Briggs, J.; Cowfer, D.; Tom, S.; Gawlitzek, M.; Lofgren, J.; Mehta, S.; Chisholm, V.; Modi, N.; Eppler, S.; Carroll, K.; Chamow, S.; Peers, D.; Berman, P.; Krummen, L. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat. Biotechnol., 1999, 17, 1116-21.
31. Elliott, S.; Lorenzini, T.; Asher, S.; Aoki, K.; Brankow, D.; Buck, L.; Busse, L.; Chang, D.; Fuller, J.; Grant, J.; Hernday, N.; Hokum, M.; Hu, S.; Knudten, A.; Levin, N.; Komorowski, R.; Martin, F.; Navarro, R.; Osslund, T.; Rogers, G.; Rogers, N.; Trail, G.; Egrie, J. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat. Biotechnol., 2003, 21, 414-21.
32. Sherwood, J.B.; Carmichael, L.D.; Goldwasser, E. The heterogeneity of circulating human serum erythropoietin. Endocrinology, 1988, 122, 1472-7.
33. Sohmiya, M.; Kato, Y. Molecular and electrical heterogeneity of circulating human erythropoietin measured by sensitive enzyme immunoassay. Eur. J. Clin. Invest., 2000, 30, 344-9.
34. Skibeli, V.; Nissen-Lie, G.; Torjesen, P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood, 2001, 98, 3626-34.
35. Storring, P.L.; Yuen, C.T. Differences between the N-glycans of human serum erythropoietin and recombinant human erythropoietin. Blood, 2003, 101, 1204-5.
36. Jelkmann, W.; Bohlius, J.; Hallek, M.; Sytkowski, A.J. The erythropoietin receptor in normal and cancer tissues. Crit. Rev. Oncol. Hematol., 2008, 67, 39-61.
37. Livnah, O.; Stura, E.A.; Johnson, D.L.; Middleton, S.A.; Mulcahy, L.S.; Wrighton, N.C.; Dower, W.J.; Jolliffe, L.K.; Wilson, I.A. Functional mimicry of a protein hormone by a peptide agonist: The EPO receptor complex at 2.8 A. Science, 1996, 273, 464-71.
38. Wrighton, N.C.; Farrell, F.X.; Chang, R.; Kashyap, A.K.; Barbone, F.P.; Mulcahy, L.S.; Johnson, D.L.; Barrett, R.W.; Jolliffe, L.K.; Dower, W.J. Small peptides as potent mimetics of the protein hormone erythropoietin. Science, 1996, 273, 458-64.
39. Egrie, J.C.; Browne, J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br. J. Cancer, 2001, 84, 3-10.
40. Darling, R.J.; Kuchibhotla, U.; Glaesner, W.; Micanovic, R.; Witcher, D.R.; Beals, J.M. Glycosylation of erythropoietin affects receptor binding kinetics: Role of electrostatic interactions. Biochemistry, 2002, 41, 14524-31.
41. Tauchi, T.; Feng, G.S.; Shen, R.; Hoatlin, M.; Bagby, G.C. Jr.; Kabat, D.; Lu, L.; Broxmeyer, H.E. Involvement of SH2-containing phosphotyrosine phosphatase Syp in erythropoietin receptor signal transduction pathways. J. Biol. Chem., 1995, 270, 5631-5.
42. Barber, D.L.; Beattie, B.K.; Mason, J.M.; Nguyen, M.H.H.; Yoakim, M.; Neel, B.G.; D'Andrea, A.D.; Frank, D.A. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: Implications for the docking model of STAT activation. Blood, 2001, 97, 2230-7.
43. Koury, M.J.; Bondurant, M.C. The molecular mechanism of erythropoietin action. Eur. J. Biochem., 1992, 210, 649-63.
44. Cotes, P.M.; Bangham, D.R. The international reference preparation of erythropoietin. Bull. World Health Organ., 1966, 35, 751-60.
45. Annable, L.; Cotes, P.M.; Mussett, M.V. The second international reference preparation of erythropoietin, human, urinary, for bioassay. Bull. World Health Organ., 1972, 47, 99-112.
46. Storring, P.L.; Gaines Das R.E. The International Standard for Recombinant DNA-derived Erythropoietin: Collaborative study of four recombinant DNA-derived erythropoietins and two highly purified human urinary erythropoietins. J. Endocrinol., 1992, 134, 459-84.
47. European Directorate for the Quality of Medicines & Health Care. 2008. http://crs.edqm.eu/db/4DCGI/db/4DCGI/leaflet?leaflet= E1515000_3
48. Sodoyer, R. Expression systems for the production of recombinant pharmaceuticals. BioDrugs, 2004, 18, 51-62.
49. Helenius, A.; Aebi, M. Intracellular functions of N-linked glycans. Science, 2001, 291, 2364-9.
50. Goto, M.; Akai, K.; Murakami, A.; Haschimoto, C.; Tsuda, E.; Ueda, M.; Kawanishi, G.; Takahashi, N.; Ishimoto, A.; Chiba, H.; Sasaki, R. Production of recombinant human erythropoietin in mammalian cells: Host-cell dependency of the biological activity of the cloned glycoprotein. Bio/Technology, 1988, 6, 67-71.
51. Hayakawa, T.; Wada, M.; Mizuno, K.; Abe, S.; Miyashita, M.; Ueda, M. In vivo biological activities of recombinant human erythropoietin analogues produced by CHO cells, BHK cells and C127 cells. Biologicals, 1992, 20, 253-7.
52. Lin, F.K.; Suggs, S.; Lin, C.H.; Browne, J.K.; Smalling, R.; Egrie, J.C.; Chen, K.K.; Fox, G.M.; Martin, F.; Stabinsky, Z.; Badrawi, S.M.; Lai, P.H.; Goldwasser, E. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA, 1985, 82, 7580-4.
53. Egrie, J.C.; Strickland, T.W.; Lane, J.; Aoki, K.; Cohen, A.M.; Smalling, R.; Trail, G.; Lin, F.K.; Browne, J.K.; Hines, D.K. Characterization and biological effects of recombinant human erythropoietin. Immunobiology, 1986, 172, 213-24.
54. Takeuchi, M.; Inoue, N.; Strickland, T.W.; Kubota, M.; Wada, M.; Shimizu, R.; Hoshi, S.; Kozutsumi, H.; Takasaki, S.; Kobata, A. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc. Natl. Acad. Sci. USA, 1989, 86, 7819-22.
55. Davis, J.M.; Arakawa, T.; Strickland, T.W.; Yphantis, D.A. Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry, 1987, 26, 2633-8.
56. World Health Organization: International nonproprietary names (INN) for biological and biotechnological substances. http://www.who.int/ medicines/services/inn/CompleteBioRevdoc%2008-11-07_2_.pdf.
57. Hokke, C.H.; Bergwerff, A.A.; van Dedem, G.W.; van Oostrum, J.; Kamerling, J.P.; Vliegenthart, J.F. Sialylated carbohydrate chains of recombinant human glycoproteins expressed in Chinese hamster ovary cells contain traces of N-glycolylneuraminic acid. FEBS Lett., 1990, 275, 9-14.
58. Hokke, C.H.; Bergwerff, A.A.; van Dedem, G.W.; Kamerling, J.P.; Vliegenthart, J.F. Structural analysis of the sialylated N- and Olinked carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. Sialylation patterns and branch location of dimeric N-acetyllactosamine units. Eur. J. Biochem., 1995, 228, 981-1008.
59. Storring, P.L.; Tiplady, R.J.; Gaines Das, R.; Stenning, B.E.; Lamikanra, A.; Rafferty, B.; Lee, J. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol., 1998, 100, 79-89.
60. US Patent 5856298 - Erythropoietin isoforms. http:// www.patentstorm.us/patents/5856298/fulltext.html.
61. Ramakrishnan, R.; Cheung, W.K.; Wacholtz, M.C.; Minton, N.; Jusko, W.J. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol., 2004, 44, 991-1002.
62. Kohler, M.; Ayotte, C.; Desharnais, P.; Flenker, U.; Ludke, S.; Thevis, M.; Vl̈ker-Schänzer, E.; Schänzer, W. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int. J. Sports Med., 2008, 29, 1-6.
63. Takeuchi, M.; Takasaki, S.; Miyazaki, H.; Kato, T.; Hoshi, S.; Kochibe, N.; Kobata, A.: Comparative study of the asparagine-linked sugar chains of human erythropoietins purified from urine and the culture medium of recombinant Chinese hamster ovary cells. J. Biol. Chem., 1988, 263, 3657-63.
64. Groleau, P.E.; Desharnais, P.; Coté, L.; Ayotte, C. Low LCMS/MS detection of glycopeptides released from pmol levels of recombinant erythropoietin using nanoflow HPLC-chip electrospray ionization. J. Mass Spectrom, 2008, 43, 924-35.
65. Powell, J.S.; Berkner, K.L.; Lebo, R.V.; Adamson, J.W. Human erythropoietin gene: High level expression in stably transfected mammalian cells and chromosome localization. Proc. Natl. Acad. Sci. USA, 1986, 83, 6465-9.
66. Tsuda, E.; Goto, M.; Murakami, A.; Akai, K.; Ueda, M.; Kawanishi, G.; Takahashi, N.; Sasaki, R.; Chiba, H.; Ishihara, H. Comparative structural study of N-linked oligosaccharides of urinary and recombinant erythropoietins. Biochemistry, 1988, 27, 5646-54.
67. Nimtz, M.; Wray, V.; Rüdiger, A.; Conradt, H. S.: Identification and structural characterization of a mannose-6-phosphate containing oligomannosidic N-glycan from human erythropoietin secreted by recombinant BHK-21 cells. FEBS Lett., 1995, 365, 203-8.
68. Kawasaki, N; Haishima, Y.; Ohta, M.; Itoh, S.; Hyuga, M.; Hyuga, S.; Hayakawa, T. Structural analysis of sulfated N-linked oligosaccarides in erythropoietin. Glycobiology, 2001, 11, 1043-9.
69. Sinclair, A.M.; Elliott, S. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci., 2005, 94, 1626-35.
70. Macdougall, I.C.: Novel erythropoiesis stimulating protein. Semin. Nephrol., 2000, 20, 375-81.
71. Wide, L.; Wikstrom, B.; Eriksson, K. A new principle suggested for detection of darbepoetin-alpha (NESP) doping. Ups. J. Med. Sci., 2003, 108, 229-38.
72. Gore, C.J.; Parisotto, R.; Ashenden, M.J.; Stray-Gundersen, J.; Sharpe, K.; Hopkins, W.; Emslie, K.R.; Howe, C.; Trout, G.J.; Kazlauskas, R.; Hahn, A.G. Second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica, 2003, 88, 333-44.
73. Jelkmann, W.: The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur. J. Haematol., 2002, 69, 265-74.
74. Misaizu, T.; Matsuki, S.; Strickland, T.W.; Takeuchi, M.; Kobata, A.; Takasaki, S. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood, 1995, 86, 4097-104.
75. Lasne, F.; de Ceaurriz, J. Recombinant erythropoietin in urine. Nature, 2000, 405, 635.
76. Catlin, D.H.; Breidbach, A.; Elliott, S.; Glaspy, J. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin. Chem., 2002, 48, 2057-9.
77. Pascual, J.A.; Belalcazar, V.; de Bolos, C.; Gutierrez, R.; Llop, E.; Segura, J. Recombinant erythropoietin and analogues: A challenge for doping control. Ther. Drug Monit., 2004, 26, 175-9.
78. Wide, L.; Bengtsson, C.; Berglund, B.; Ekblom, B. Detection in blood and urine of recombinant erythropoietin administered to healthy men. Med. Sci. Sports Exerc., 1995, 27, 1569-76.
79. Lasne, F.: Aouble-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J. Immunol. Methods, 2001, 253, 125-31.
80. Lasne, F.; Martin, L.; Crepin, N.; de Ceaurriz, J. Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones. Anal. Biochem., 2002, 311, 119-26.
81. Giménez, E.; de Bolós, C.; Belalcazar, V.; Andreu, D.; Borrás, E.; De la Torre, B.G.; Barbosa, J.; Segura, J.; Pascual, J.A. Anti-EPO and anti-NESP antibodies raised against synthetic peptides that reproduce the minimal amino acid sequence differences between EPO and NESP. Anal. Bioanal. Chem., 2007, 388, 1531-8.
82. WADA: Harmonization of the method for the identification of Epoetin alfa and beta (EPO) and Darbepoetin alfa (NESP) by IEF-double blotting and chemiluminescent detection. http://www.wadaama.org/rtecontent/ document/td2007epo_en.pdf.
83. Lasne, F.; Martin, L.; Martin, J.A.; de Ceaurriz, J. Isoelectric profiles of human erythropoietin are different in serum and urine. Int. J. Biol. Macromol., 2007, 41, 354-7.
84. Sytkowski, A.J.; Fisher, J.W. Isolation and characterization of an anti-peptide monoclonal antibody to human erythropoietin. J. Biol. Chem., 1985, 260, 14727-31.
85. Bajla, I.; Holländer, I.; Minichmayr, M.; Gmeiner, G.; Reichel, C. GASepo-a software solution for quantitative analysis of digital images in Epo doping control. Comput. Methods Prog. Biomed., 2005, 80, 246-70.
86. Lasne, F.; Thioulouse, J.; Martin, L.; de Ceaurriz, J. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis, 2007, 28, 1875-81.
87. Belalcazar, V.; Gutierrez, G.R.; Llop, E.; Segura, J.; Pascual, J.A.: Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine. Electrophoresis, 2006, 27, 4387-95.
88. Franke, W.W.; Heid, H. Pitfalls, errors and risks of false-positive results in urinary EPO drug tests. Clin. Chim. Acta, 2006, 373, 189-90.
89. Beullens, M.; Delanghe, J.R.; Bollen, M. False-positive detection of recombinant human erythropoietin in urine following strenuous physical exercise. Blood, 2006, 107, 4711-3.
90. Reichel, C. Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. J. Mass Spectrom, 2008, 43, 916-23.
91. Khan, A.; Baker, M.S. Non-specific binding of monoclonal human erythropoietin antibody AE7A5 to Escherichia coli and Saccharomyces cerevisiae proteins. Clin. Chim. Acta, 2007, 379, 173-5.
92. Khan, A.; Grinyer, J.; Truong, S.T.; Breen, E.J.; Packer, N.H. New urinary EPO drug testing method using two-dimensional gel electrophoresis. Clin. Chim. Acta, 2005, 358, 119-30.
93. Dou, P.; Liu, Z.; He, J.; Xu, J.J.; Chen, H.Y. Rapid and high-resolution glycoform profiling of recombinant human erythropoietin by capillary isoelectric focusing with whole column imaging detection. J. Chromatogr. A, 2008, 1190, 372-6.
94. Nagano, M.; Stubiger, G.; Marchetti, M.; Gmeiner, G.; Allmaier, G.; Reichel, C. Detection of isoforms of recombinant human erythropoietin by various plant lectins after isoelectric focusing. Electrophoresis, 2005, 26, 1633-45.
95. Stübiger, G.; Marchetti, M.; Nagano, M.; Grimm, R.; Gmeiner, G.; Reichel, C.; Allmaier, G. Characterization of N- and Oglycopeptides of recombinant human erythropoietins as potential biomarkers for doping analysis by means of microscale sample purification combined with MALDI-TOF and quadrupole IT/RTOF mass spectrometry. J. Sep. Sci., 2005, 28, 1764-78.
96. Stübiger, G.; Marchetti, M.; Nagano, M.; Reichel, C.; Gmeiner, G.; Allmaier, G. Characterisation of intact recombinant human erythropoietins applied in doping by means of planar gel electrophoretic techniques and matrix-assisted laser desorption/ionisation linear time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom., 2005, 19, 728-42.
97. Lundby, C.; Achman-Andersen, N. J.; Thomsen, J. J.; Norgaard, A. M.; Robach, P. Testing for recombinant human erythropoietin in urine: problems associated with current anti doping testing. J. Appl. Physiol., 2008, 105, 417-9.
98. Westgard, J.O.; Burnett, R.W.; Bowers, G.N. Quality management science in clinical chemistry: A dynamic framework for continuous improvement of quality. Clin. Chem., 1990, 36, 1712-6.
99. Lamon, S.; Robinson, N.; Sottas, P. E.; Henry, H.; Kamber, M.; Mangin, P.; Saugy, M. Possible origins of undetectable EPO in urine samples. Clin. Chim. Acta, 2007, 385, 61-6.
100. Thevis, M.; Maurer, J.; Kohler, M.; Geyer, H.; Schänzer, W. Proteases in doping control analysis. Int. J. Sports Med., 2007, 28, 545-9.
101. Ashenden, M.; Varlet-Marie, E.; Lasne, F.; Audran, M. The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica, 2006, 91, 1143-4.
102. Breidbach, A.; Catlin, D.H.; Green, G.A.; Tregub, I.; Truong, H.; Gorzek, J. Detection of recombinant human erythropoietin in urine by isoelectric focusing. Clin. Chem., 2003, 49, 901-7.
103. Lamon, S.; Robinson, N.; Mangin, P.; Saugy, M.: Detection window of Darbepoetin-alpha following one single subcutaneous injection. Clin. Chim. Acta, 2007, 379, 145-9.
104. Morkeberg, J.; Lundby, C.; Nissen-Lie, G.; Nielsen, T. K.; Hemmersbach, P.; Damsgaard, R. Detection of darbepoetin alfa misuse in urine and blood: A preliminary investigation. Med. Sci. Sports Exerc., 2007, 39, 1742-7.
105. Mallorqui, J.; Segura, J.; de Bolòs, C.; Gutiérrez-Gallego, R.; Pascual, J.A. Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica, 2008, 93, 313-4.
106. EMEA. Dynepo. Scientific discussion. http://www.emea.europa.eu/ humandocs/Humans/EPAR/dynepo/dynepo.htm.
107. hmcourts-service.gov.uk. The Court Service - Court of Appeal - Civil - Judgment 2002, EWCA Civ. 1096, www.hmcourtsservice.gov.uk/ judgmentsfiles/j1329/Kirin_v_Hoechst.htm.
108. Varki, A. Loss of N-glycolylneuraminic acid in humans: Mechanisms, consequences, and implications for hominid evolution. Am. J. Phys. Anthropol., 2001, Suppl. 33, 54-69.
109. Llop, E.; Gutiérrez-Gallego, R.; Segura, J.; Mallorqui, J.; Pascual, J.A. Structural analysis of the glycosylation of gene-activated erythropoietin (epoetin Delta, Dynepo). Anal. Biochem., 2008, 383, 243-54.
110. Smith, W.B.; Dowell, J.A.; Pratt, R.D. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clin. Ther., 2007, 29, 1368-80.
111. EMEA. HX575. Scientific discussion. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/epoetinalfahexal/H-726-en6.pdf.
112. EMEA. SB 309. Scientific discussion. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/silapo/H-760-en6.pdf.
113. Park, S.S.; Park, J.; Ko, J.; Chen, L.; Meriage, D.; Crouse-Zeineddini, J.; Wong, W.; Kerwin, B.A. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm. Sci. 2008, in press.
114. Perez-Oliva, J.F.; Casanova-Gonzalez, M.; Garcia-Garcia, I.; Porrero-Martin, P.J.; Valenzuela-Silva, C.M.; Hernandez-Montero, T.; Lagarde-Ampudia, M.; Casanova-Kutsareva, Y.; Avila- Albuerne, Y.; Vargas-Batista, A.; Bobillo-Lopez, H.; Herrera-Valdes, R.; Lopez-Saura, P.A. Comparison of two recombinant erythropoietin formulations in patients with anemia due to endstage renal disease on hemodialysis: A parallel, randomized, double blind study. BMC Nephrology, 2005, 6, 5.
115. Thitiarchakul, S.; Tasanarong, A. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis. J. Med. Assoc. Thai., 2007, 90, 636-42.
116. Goh, B.L.; Ong, L. M.; Sivanandam, S.; Lim, T. O.; Morad, Z. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis. Nephrology (Carlton), 2007, 12, 431-6.
117. Wurm, F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol., 2004, 22, 1393-8.
118. Combe, C.; Tredree, R.L.; Schellekens, H. Biosimilar epoetins: An analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy, 2005, 25, 954-62.
119. Schellekens, H. Biosimilar epoetins: How similar are they? Eur. J. Hosp. Pharm., 2004, 3, 43-7.
120. FDA. http://www.fda.gov/medwatch/SAFETY/2002/epogen.htm.
121. Delgado, C.; Francis, G.E.; Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst., 1992, 9, 249-304.
122. Mehvar, R. Modulation of the pharmacokinetics and pharmacodynamics of proteins by polyethylene glycol conjugation. J. Pharm. Pharmacol., 2000, 3, 125-36.
123. Macdougall, I.C. CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep., 2005, 4, 436-40.
124. Kochendoerfer, G.G.; Chen, S.Y.; Mao, F.; Cressman, S.; Traviglia, S.; Shao, H.; Hunter, C.L.; Low, D.W.; Cagle, E.N.; Carnevali, M.; Gueriguian, V.; Keogh, P.J.; Porter, H.; Stratton, S.M.; Wiedeke, M.C.; Wilken, J.; Tang, J.; Levy, J.J.; Miranda, L.P.; Crnogorac, M.M.; Kalbag, S.; Botti, P.; Schindler-Horvat, J.; Savatski, L.; Adamson, J.W.; Kung, A.; Kent, S.B.; Bradburne, J.A. Design and chemical synthesis of a homogeneous polymermodified erythropoiesis protein. Science, 2003, 299, 884-7.
125. Chen, S.Y.; Cressman, S.; Mao, F.; Shao, H.; Low, D.W.; Beilan, H.S.; Cagle, E.N.; Carnevali, M.; Gueriguian, V.; Keogh, P.J.; Porter, H.; Stratton, S.M.; Wiedeke, M.C.; Savatski, L.; Adamson, J.W.; Bozzini, C.E.; Kung, A.; Kent, S.B.; Bradburne, J.A.; Kochendoerfer, G.G. Synthetic erythropoietic proteins: Tuning biological performance by site-specific polymer attachment. Chem. Biol., 2005, 12, 371-83.
126. Kochendoerfer, G.G. Site-specific polymer modification of therapeutic proteins. Curr. Opin. Chem. Biol., 2005, 9, 555-60.
127. Lee, D.E.; Son, W.; Ha, B. J.; Oh, M. S.; Yoo, O. J. The prolonged half-lives of new erythropoietin derivatives via peptide addition. Biochem. Biophys. Res. Commun., 2006, 339, 380-5.
128. Fares, F.; Ganem, S.; Hajouj, T.; Agai, E. Development of a long acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. Endocrinology, 2007, 148, 5081-7.
129. Sytkowski, A.J.; Lunn, E.D.; Risinger, M.A.; Davis, K.L. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J. Biol. Chem., 1999, 274, 24773-8.
130. Dalle, B.; Henri, A.; Rouyer-Fessard, P.; Bettan, M.; Scherman, D.; Beuzard, Y.; Payen, E. Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo. Blood, 2001, 97, 3776-82.
131. Way, J.C.; Lauder, S.; Brunkhorst, B.; Kong, S.M.; Qi, A.; Webster, G.; Campbell, I.; McKenzie, S.; Lan, Y.; Marelli, B.; Nguyen, L.A.; Degon, S.; Lo, K.M.; Gillies, S.D. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel., 2005, 18, 111-8.
132. Dumont, J.A.; Bitonti, A.J.; Clark, D.; Evans, S.; Pickford, M.; Newman, S.P. Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol. Med., 2005, 18, 294-303.
133. Johnson, D.L.; Farrell, F.X.; Barbone, F.P.; McMahon, F.J.; Tullai, J.; Kroon, D.; Freedy, J.; Zivin, R.A.; Mulcahy, L.S.; Jolliffe, L.K. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem. Biol., 1997, 4, 939-50.
134. Fan, Q.; Leuther, K.K.; Holmes, C.P.; Fong, K.L.; Zhang, J.; Velkovska, S.; Chen, M.J.; Mortensen, R.B.; Leu, K.; Green, J.M.; Schatz, P.J.; Woodburn, K.W. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp. Hematol., 2006, 34, 1303-11.
135. Stead, R.B.; Lambert, J.; Wessels, D.; Iwashita, J.S.; Leuther, K.K.; Woodburn, K.W.; Schatz, P.J.; Okamoto, D.M.; Naso, R.; Duliege, A.M. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood, 2006, 108, 1830-4.
136. Woo, S.; Krzyzanski, W.; Duliege, A.M.; Stead, R.B.; Jusko, W.J. Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol., 2008, 48, 43-52.
137. Bouman-Thio, E.; Franson, K.; Miller, B.; Getsy, J.; Cohen, A.; Bai, S.A.; Yohrling, J.; Frederick, B.; Marciniak, S.; Jiao, Q.; Jang, H.; Davis, H.; Burggraaf, J. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J. Clin. Pharmacol., 2008, 48, 1197-207.
138. Qureshi, S.A.; Kim, R.M.; Konteatis, Z.; Biazzo, D.E.; Motamedi, H.; Rodrigues, R.; Boice, J.A.; Calaycay, J.R.; Bednarek, M.A.; Griffin, P.; Gao, Y.D.; Chapman, K.; Mark, D.F. Mimicry of erythropoietin by a nonpeptide molecule. Proc. Natl. Acad. Sci. USA, 1999, 96, 12156-61.
139. Goldberg, J.; Jin, Q.; Ambroise, Y.; Satoh, S.; Desharnais, J.; Capps, K.; Boger, D.L. Erythropoietin mimetics derived from solution phase combinatorial libraries. J. Am. Chem. Soc., 2002, 124, 544-55.
140. Nakano, Y.; Imagawa, S.; Matsumoto, K.; Stockmann, C.; Obara, N.; Suzuki, N.; Doi, T.; Kodama, T.; Takahashi, S.; Nagasawa, T.; Yamamoto, M. Oral administration of K-11706 inhibits GATA binding activity, enhances hypoxia-inducible factor 1 binding activity, and restores indicators in an in vivo mouse model of anemia of chronic disease. Blood, 2004, 104, 4300-7.
141. Imagawa, S.; Matsumoto, K.; Horie, M.; Ohkoshi, N.; Nagasawa, T.; Doi, T.; Suzuki, N.; Yamamoto, M. Does K-11706 enhance performance and why? Int. J. Sports Med., 2007, 28, 928-33.
142. Fandrey, J.: Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2004, 286, R977-R988.
143. Schofield, C.J.; Ratcliffe, P.J. Signalling hypoxia by HIF hydroxylases. Biochem. Biophys. Res. Commun., 2005, 338, 617-26.
144. Bruegge, K.; Jelkmann, W.; Metzen, E. Hydroxylation of hypoxiainducible transcription factors and chemical compounds targeting the HIF- hydroxylases. Curr. Med. Chem., 2007, 14, 1853-62.
145. Kling, P.J.; Dragsten, P.R.; Roberts, R.A.; Dos-Santos, B.; Brooks, D.J.; Hedlund, B.E.; Taetle, R. Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy. Br. J. Haematol., 1996, 95, 241-8.
146. Ren, X.; Dorrington, K.L.; Maxwell, P.H.; Robbins, P.A. Effects of desferrioxamine on serum erythropoietin and ventilatory sensitivity to hypoxia in humans. J. Appl. Physiol., 2000, 89, 680-6.
147. Weissbecker, L. Die Kobalttherapie. Dtsch. Med. Wochenschr., 1950, 75, 116-8.
148. Thevis, M.; Schänzer, W. Emerging drugs - potential for misuse in sport and doping control detection strategies. Mini Rev. Med. Chem., 2007, 7, 531-7.
149. Ivan, M.; Haberberger, T.; Gervasi, D.C.; Michelson, K.S.; Günzler, V.; Kondo, K.; Yang, H.; Sorokina, I.; Conaway, R.C.; Conaway, J.W.; Kaelin, W.G.J. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl. Acad. Sci. USA, 2002, 99, 13459-64.
150. FibroGen, 2008, http://www. fibrogen.com/rd/hif/epo.html.
151. Klaus, S.J.; Molineaux, C.J.; Neff, T.B.; Guenzler-Pukall, V.; Langsetmo Parobok, I.; Seeley, T.W.; Stephenson, R.C. Enhanced erythropoiesis and iron metabolism. 2005, http://www.freepatentsonline.com/ 20050020487.html.
152. Hsieh, M.M.; Linde, N.S.; Wynter, A.; Metzger, M.; Wong, C.; Langsetmo, I.; Lin, A.; Smith, R.; Rodgers, G.P.; Donahue, R.E.; Klaus, S.J.; Tisdale, J.F. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood, 2007, 110, 2140-7.
153. Astellas Pharma Inc. Adverse event of FG-2216 for the treatment of anemia. 2007, http://www. astellas.com/global/about/news/ 2007/pdf/070507_eg.pdf.
154. Jelkmann, W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol., 2007, 435, 179-97.
155. Binley, K.; Askham, Z.; Iqball, S.; Spearman, H.; Martin, L.; de Alwis,
156. Lasne, F.; Martin, L.; de Ceaurriz, J.; Larcher, T.; Moullier, P.; Chenuaud, P. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol. Ther., 2004, 10, 409-10.
157. Gao, G.; Lebherz, C.; Weiner, D.J.; Grant, R.; Calcedo, R.; McCullough, B.; Bagg, A.; Zhang, Y.; Wilson, J.M. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood, 2004, 103, 3300-2.
158. Chenuaud, P.; Larcher, T.; Rabinowitz, J.E.; Provost, N.; Cherel, Y.; Casadevall, N.; Samulski, R.J.; Moullier, P. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood, 2004, 103, 3303-4.
159. Lippin, Y.; Dranitzki-Elhalel, M.; Brill-Almon, E.; Mei-Zahav, C.; Mizrachi, S.; Liberman, Y.; Iaina, A.; Kaplan, E.; Podjarny, E.; Zeira, E.; Harati, M.; Casadevall, N.; Shani, N.; Galun, E. Human erythropoietin gene therapy for patients with chronic renal failure. Blood, 2005, 106, 2280-6.
160. Berglund, B.; Ekblom, B.; Ekblom, E.; Berglund, L.; Kallner, A.; Reinebo, P.; Lindeberg, S. The Swedish Blood Pass project. Scand. J. Med. Sci. Sports, 2007, 17, 292-7.